,i #aahth ,,congress #ast ,session ,h4 ,r4 #dfbf ,,in ,,the ,,house ,,of ,,representatives ,july #ac1 #bjbc,mrs4 ,miller-,meeks 7for herself1 ,mrs4 ,kiggans of ,virginia1 ,ms4 ,greene of ,georgia1 ,mrs4 ,bice1 ,ms4 ,salazar1 ,mrs4 ,chavez-,de,remer1 ,ms4 ,malliotakis1 ,mrs4 ,kim of ,california1 ,mrs4 ,harshbarger1 and ,ms4 ,mace7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to encourage sponsors of oral contraceptive drugs to submit applications for the approval of such drugs as over-the-counter1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,orally ,taken ,contraception ,act of #bjbc or the ,,otc ,act of #bjbc4 #b4 ,,fda guidance on changing marketing status of contraceptive drugs to over-the-counter 7a7 ,in general ,not later than #a year after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services acting through the ,commissioner of ,food and ,drugs1 for purposes of encouraging sponsors of oral contraceptive drugs to submit applications for the approval of oral contraceptive drugs to be marketed without being subject to section #ejc7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;b77#a771 shall issue guidance that-- 7#a7 provides a detailed description of the review process for the-- 7,a7 approval of drugs under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee72 7,b7 marketing authorization of over-the-counter drugs under section #eje;,g of such ,act 7#ba ,u4,s4,c4 #cee;h72 and 7,c7 licensure of biological products under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb72 7#b7 provides for background information on oral contraceptive drugs1 including-- 7,a7 the history of approval1 marketing authorization1 or licensure of oral contraceptive drugs under the provisions of law specified in paragraph 7#a72 7,b7 the standards used to grant such approval1 marketing authorization1 or licensure2 and 7#c7 specifies the benefit-risk considerations that the ,secretary uses to determine whether to approve1 authorize for marketing1 or license oral contraceptive drugs2 and 7#d7 details the ,secretary's efforts to facilitate the development of oral contraceptive drugs to be marketed without being subject to section #ejc7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;b77#a774 7b7 ,labeling comprehension study 7#a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall complete a study on consumer comprehension of the labeling of oral contraceptive drugs4 7#b7 ,issues to be studied ,the study required by paragraph 7#a7 shall address how the labeling of oral contraceptive drugs could be improved to increase consumer comprehension of the information conveyed in such labeling1 including the proper use of such drugs and for whom such drugs are indicated4 7#c7 ,completion2 publication ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall-- 7,a7 not later than #a year after the date of the enactment of this ,act1 complete the study required by paragraph 7#a72 and 7,b7 publish the results of such study in conjunction with the issuance of the guidance required by subsection 7a74 7c7 ,oral contraceptive drug defined ,in this section1 the term oral contraceptive drug means a drug 7as defined in section #bja7;g77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;g77#a77 that-- 7#a7 is used to prevent fertilization2 7#b7 is administered orally2 7#c7 is solely intended for routine use and not as an emergency contraceptive2 7#d7 does not include any drug1 substance1 or combination of drugs or substances used after fertilization2 and 7#e7 does not include any drug or other method used to terminate a pregnancy4